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The epidermal growth factor (EGF) family comprises
multiple mediators such as transforming growth
factor-a, amphiregulin, heparin binding-EGF, and
epiregulin, which are crucially involved in the tissue-
specific proliferation/differentiation homeostasis. Ty-
pically, they act in an autocrine and paracrine manner
on their specific cell membrane receptor and mount
an effective reparative response to any attack to
biophysical integrity. In addition, the EGFR can be
activated by transactivation from a variety of
G-protein-coupled receptors, integrins, and cytokine
receptors, so that it acts as the major transducer of
disparate cell functions, including changes in prolif-
eration rate, cellular shape, attachment and motility,
and regulation of proinflammatory activation. How-
ever, numerous experimental observations indicate
that the different EGFR ligands are not redundant, but
may rather provide distinct and specific contributions
to keratinocyte functions. Importantly, increasing
evidence now suggests that the EGFR pathway has a
major impact on the inflammatory/immune reactions
of the skin, in the apparent effort of enhancing innate
immune defense while opposing overactivation of
keratinocyte pro-inflammatory functions. This review
covers the molecular mechanisms and functions
activated by this major growth factor system in the
regulation of keratinocyte biology and focuses on
the complex contribution of EGFR signaling to the
inflammatory processes in the skin.
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INTRODUCTION
The epidermal growth factor (EGF) receptor signaling path-
way regulates fundamental functions in mammalian cells
including survival, migration, and proliferation. Conse-
quently, it has been deeply investigated, both experimentally
and computationally (Jost et al., 2000; Oda et al., 2005). A
family of ligands binds to distinct subtypes of erythroblastic
leukemia viral (v-erb-b) oncogene homolog (ErbB) receptors
that activate multiple molecules in an extensive network of
receptor complexes. These receptors are expressed on most
human cell types, with the possible exception of mature
hematopoietic cells. The binding of ligands induces homo-
and heterodimerization of four ErbB family receptors: ErbB1
(also universally identified as EGFR), ErbB2, ErbB3, and
ErbB4. EGFR, ErbB2, and ErbB3 are expressed in human skin,
with evidence of a functional dominance of EGFR (Stoll et al.,
2001). Indeed, epidermal keratinocytes are a rich source of
EGFR ligands, including transforming growth factor (TGF)-a
(Coffey et al., 1987), amphiregulin (Cook et al., 1991),
heparin binding (HB)-EGF (Hashimoto et al., 1994), and
epiregulin (Shirakata et al., 2000). In unstimulated condi-
tions, cultured keratinocytes display relevant levels of
amphiregulin, whereas TGF-a, HB-EGF, and epiregulin are
barely detectable at the transcript level (Shirakata et al.,
2000). EGFR immunoreactivity can be localized throughout
the whole epidermis of normal skin, although it is more
accentuated in the basal cell layer (Nanney et al., 1984;
Mascia et al., 2003).
ErbB dimer binding by a specific ligand stimulates ErbB
cytoplasmic kinase activity leading to auto- and transpho-
sphorylation on tyrosine residues, which serve as docking
sites for adaptor proteins and enzymes (Schlessinger, 2000).
Between the two lobes of the kinase fold there is the ATP
binding pocket, the focus of specific inhibitor design that
exploits differences in kinase structure to achieve selectivity.
In the last two decades, a number of effective small-molecule
inhibitors have been synthesized (Noble et al., 2004),
representing invaluable tools for the investigation of EGFR-
dependent cell events. Most importantly, they can be
clinically effective in enhancing the response to cytotoxic
drugs of EGFR-dependent tumors (Slichenmyer and Fry,
2001). The most selective compounds, which include
gefitinib and erlotinib, possess a quinazoline nucleus (Noble
et al., 2004). Broad-spectrum anti-ErbB inhibitors, such as
lapatinib or canertinib, may result in a greater efficacy and
broad spectrum of antitumor activity (Arora and Scholar,
2005). Also mAbs, including cetuximab and ABX-EGF, show
promise as chemotherapeutic agents (Kondapalli et al.,
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2005). Notably, both small-molecule EGFR inhibitors and
anti-EGFR antibodies typically exert peculiar inflammatory/
toxic effects on the skin (Lacouture, 2006), with striking
similarities with phenotypes of mice with reduced EGFR
function (Roberts et al., 2004).
DISPARATE MECHANISMS OF EGFR ACTIVATION
EGFR can be activated by several mechanisms under
physiological or pathophysiological conditions. Apart from
direct activation by specific ligands, heterologous ligand-
dependent mechanisms are also at work, as demonstrated by
the finding that stimulation of a number of G-protein-coupled
receptors (GPCRs) results in EGFR activation via metallopro-
teinase-mediated cleavage of the mature form of EGFR
ligands from membrane precursors (Figure 1). During wound
healing, angiotensin II stimulates keratinocyte and fibroblast
migration through a pathway initiated by the GPCR
angiotensin II receptor that leads to HB-EGF shedding and
consequent extracellular signal-regulated kinase (ERK) cas-
cade activation (Yahata et al., 2006). Not only specific
antagonism to angiotensin II receptor, but also to EGFR, as
well as inhibition of the extracellular metalloproteinases can
efficiently abrogate angiotensin II pro-healing activity.
Similarly, keratinocyte-released catecholamines can stimu-
late keratinocyte migration and wound re-epithelialization
through a mechanism that requires both EGFR and ERK
activation (Pullar and Isseroff, 2006). The existence of this
‘‘triple-membrane-passing-signal’’ mechanism (Gschwind
et al., 2001) underlying inter-receptor signal transmission
is now well documented, and is certainly not confined
exclusively to GPCR-triggered cell responses. We could
recently demonstrate that both TNF-a and IFN-g can activate
this mechanism in human keratinocytes, with consequent
induction of EGFR phosphorylation and EGFR-dependent
ERK activation (Mascia et al., 2003). EGFR can be activated
also through EGFR ligand-independent mechanisms. Integ-
rins form physical complexes at the cell membrane with
growth factor receptors, giving rise to cooperative signaling
platforms at the adhesive sites (Cabodi et al., 2004). Active
protein-tyrosine phosphatases can limit EGFR functions
through its dephosphorylation (Xu et al., 2005). In turn, the
generation of reactive oxygen species secondary to EGFR
activation leads to the reversible inactivation of crucial
protein-tyrosine phosphatases by oxidizing the catalytic
cysteine in their active site. Noteworthy, oxidative inhibition
of protein-tyrosine phosphatase activity by reactive oxygen
species underlies EGFR activation by UV irradiation
(Xu et al., 2006).
MOLECULAR EVENTS AND CELL FUNCTIONS DRIVEN
BY EGFR
The EGFR–ERK pathway plays a crucial role in mediating
both the pro-survival and proliferative programs of keratino-
cytes. Indeed, human epidermal keratinocytes maintain high
steady-state levels of ERK activity essentially via their
autocrine production of EGFR ligands (Iordanov et al.,
2002). The classical signal-transduction cascade that trans-
lates EGFR activation into the increased activity of ERK has
been extensively investigated (Schlessinger, 2000; Wetzker
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Figure 1. Mechanisms of EGFR activation in keratinocytes. In unstimulated conditions, EGFR contributes to stabilize its own activation via an autocrine/
paracrine loop based on de novo synthesis and shedding of mature EGFR ligands (1). A variety of G-protein-coupled receptor (GPCR) ligands (2), but also pro-
inflammatory cytokines binding their specific receptors (R) (3) promote a rapid metalloproteinase (MMP)-mediated shedding of EGFR ligands from membrane
precursors. In addition, after cell–matrix adhesion, integrins associate with the EGFR to trigger downstream signaling through its ligand-independent
phosphorylation (4). Finally, inactivation of protein tyrosine phosphatases (PTP) by intracellular generation of reactive oxygen species (ROS) in response to pro-
oxidative stimuli (5) allows the maintenance of EGFR in its activated form, with eventual stimulation of ERK activity.
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activated EGFR bind a number of other signaling proteins
containing phosphotyrosine-binding domains, including
phospholipase C-g1 and the p85a subunit of phosphatidyli-
nositol 3-kinase. In the phosphatidylinositol 3-kinase-depen-
dent pathway, the phosphorylation of the serine–threonine
kinase Akt results in the phosphorylation of a host of other
proteins that improve cell survival (Cantley, 2002). The
following subtitles will briefly overview major cell functions
overtly under the control of EGFR signaling.
Pro-survival programs and protection from apoptosis
Blockade of EGFR signaling either by a specific antibody or
by a small-molecule inhibitor does not induce keratinocyte
cell death, but rather enhances susceptibility to cell death
induction. Similar effects can be observed following ERK
inhibition. By contrast, the antiapoptotic response triggered
in keratinocytes after UVB is totally driven by EGFR-activated
phosphatidylinositol 3-kinase–Akt pathway (Canguilhem
et al., 2005) and represents the successful effort to overcome
the variety of UVB-induced pro-apoptotic signals. Indeed,
rapid and sustained EGFR activation is a well-established
event in response to UVB in keratinocytes (Peus et al., 2000;
Iordanov et al., 2002), and plays a crucial role in UVB-
induced epidermal hyperplasia (El-Abaseri et al., 2006) and
eventually in the onset of nonmelanoma skin cancer. An
EGFR-dependent phosphatidylinositol 3-kinase-Akt-mediated
pro-survival response can be observed in keratinocytes also
in response to oxidative stress (Wang et al., 2000; Ravid
et al., 2002). EGFR conveys critical survival signals that delay
apoptotic death triggered by the loss of matrix interaction
(Jost et al., 2001). These ERK-dependent mechanisms may
have particular relevance to disease states in which
upregulated expression of the EGFR and/or its ligands is
commonly observed, including wound healing (Marikovsky
et al., 1993) and hyperproliferative skin diseases (Elder et al.,
1989; Mascia et al., 2003).
EGFR drives the prototypic mitogenic stimulation
In cultured human epidermal keratinocytes, activation of the
EGFR by cognate ligands mediates the autonomous replica-
tive capacity of these cells. Accordingly, specific inhibitors of
EGFR signaling block the proliferation of human keratino-
cytes in vitro (Powell et al., 1999). Amphiregulin provides by
far the strongest autocrine stimulation to cell growth
(Piepkorn et al., 1994), in keeping with the observation that
this ligand is the most abundantly expressed in unstimulated
keratinocytes (Shirakata et al., 2000), followed by HB-EGF
(Hashimoto et al., 1994). By contrast, TGF-a, a potent
inducer of itself and other EGFR ligands, does not seem to
have direct mitogenic effects on cultured keratinocytes
(Pittelkow et al., 1993), whereas there is no evidence that
epiregulin stimulates keratinocyte proliferation in vitro.
In vivo, upregulated expression of EGFR ligands is a
characteristic feature of both benign and malignant hyper-
proliferative conditions of the skin. In particular, psoriatic
lesions overexpress EGFR (Nanney et al., 1986), as well as
TGF-a (Elder et al., 1989), amphiregulin (Cook et al., 1992;
Piepkorn, 1996), HB-EGF (Stoll and Elder, 1998; Zheng et al.,
2003), and epiregulin (Shirakata et al., 2007), with amphir-
egulin more represented than TGF-a when analyzed in the
same lesions at the transcript level (Cook et al., 1992). A
humanized mAb capable of neutralizing human amphiregu-
lin not only reduces epidermal thickness of human psoriatic
lesions transplanted on the severe combined immunodefi-
cient mouse, but also inhibits the hyperplastic response that
develops in nonpsoriatic human skin after transplantation
(Bhagavathula et al., 2005). Transgenic overexpression of
TGF-a leads to tissue hyperplasia and hyperkeratosis, with
spontaneous squamous papillomas occurring at sites of
wounding in adult animals in the absence of skin inflamma-
tion (Dominey et al., 1993). By contrast, transgenic expres-
sion of amphiregulin in either basal or suprabasal epidermis
causes severe psoriasis-like hyperplasia and skin inflamma-
tion (Cook et al., 1997, 2004). On the whole, these
observations point to a strong involvement of amphiregulin
in both hyperplasia and inflammation of the psoriatic lesion.
EGFR activation underlies the hyperproliferative effects of
retinoids on skin keratinocytes. Indeed HB-EGF is markedly
induced in keratinocytes in response to retinoid treatment,
both in vitro and in vivo, and retinoid-dependent hyperpro-
liferation is impaired by EGFR inhibition (Stoll and Elder,
1998; Varani et al., 2001). In normal human skin, the
application of all trans-retinoic acids induces the specific
transcripts of both HB-EGF and amphiregulin but no increase
of TGF-a, and neutralization of either HB ligands impairs
retinoic acid-dependent epidermal hyperplasia in the organ
culture model (Rittie´ et al., 2006).
Cell adhesion and migration
Integrins are adhesive receptors formed by a- and b-subunits,
which anchor extracellular matrix proteins to the actin
cytoskeleton and mediate the adhesion of cells to extra-
cellular matrices and other cells. In the basal cells of the
epithelia, the a6b4 integrin is concentrated at hemidesmo-
somes, junctional complexes that anchor cytokeratin inter-
mediate filament networks and mediate adhesion of
epithelial cells to the underlying basement membrane
(Rezniczek et al., 1998). Integrins trigger multiple signaling
pathways, which, on the basis of differential expression and
specific localization of the receptors, are involved in cell
migration, proliferation, differentiation, and survival (Hynes,
2002). They form physical complexes at the cell membrane
with growth factor receptors, and integrin-dependent adhe-
sion triggers ligand-independent EGFR activation to trans-
duce downstream signaling; conversely, integrin-induced
signaling appears necessary for full EGFR-dependent trans-
criptional responses, including those depending on ERK
(Cabodi et al., 2004). Clearly, this bidirectional crosstalk
suggests the requirement of the cooperation between cell
matrix adhesion and EGFR to achieve full biological
responses (Bill et al., 2004).
Intercellular adhesion is strengthened by the clustering of
cadherin receptors at junctions and by the association
between cadherin complexes and the actin cytoskeleton.
Cadherin-dependent adhesion is subject to regulation by
cytoplasmic proteins, and recent work has focused on the
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role of the small GTPases Rho and Rac in the stability of
cadherins at cell–cell contacts. These two GTPases function
in signal-transduction cascade downstream of a variety of cell
surface receptors. In normal keratinocytes, cadherin receptor
clustering is sufficient to activate Rac, and cadherin-
dependent Rac activation does require EGFR signaling
(Betson et al., 2002).
EGFR ligands are potent pro-migratory factors for kerati-
nocytes (Barrandon and Green, 1987). EGFR phosphoryla-
tion-dependent disruption of a6b4 at hemidesmosomes and
their consequent disassembly is a prerequisite for normal
keratinocyte migration and squamous cell carcinoma inva-
sion (Mainiero et al., 1996; Mariotti et al., 2001). Indeed,
wounding induce immediate shedding of EGFR ligands from
keratinocyte membranes, and inhibition of this process by
metalloproteinase inhibitors cause suppression of keratino-
cyte migration that can be rescued by recombinant EGFR
ligands (Tokumaru et al., 2000). In particular, TGF-a
represents the major keratinocyte pro-motility factor present
in human serum, being responsible of more than 80% of this
activity during acute wound healing (Li et al., 2006). In this
condition, the basement membrane, which represents the
fundamental scaffold for the orchestration of epithelial
adhesion and migration, is lost, and keratinocytes must
initiate their migration to a connective tissue matrix with a
complex composition, dominated by type I collagen.
Collagenase-1 (that is, matrix metalloproteinase1) activity is
required for keratinocyte migration on a type I collagen
matrix (Pilcher et al., 1997), and its sustained production is
dependent on autocrine EGFR activation as an obligatory
intermediate step (Pilcher et al., 1999). Importantly, ERK
activation is involved also in collagen-triggered migration
(Li et al., 2004).
THE EGFR-LIGAND SYSTEM DURING WOUND HEALING
OF THE SKIN
In cutaneous wound healing, the keratinocyte plays a central
role not only as key structural cell type in the repairing skin
but also as the source of growth factors, and EGFR-mediated
proliferation and migration appear crucial in wound healing.
Acute disruption of the permeability barrier by solvents or
tape stripping in the mouse stimulates epidermal proliferation
by increased expression of amphiregulin and nerve growth
factor, but not by TGF-a (Liou et al., 1997). In the model of
regenerative wound healing provided by short-term organ
culture of human skin biopsies, amphiregulin and HB-EGF,
but not TGF-a, are both rapidly and markedly induced, with
EGFR inhibition blocking the expression of EGFR ligands and
epidermal cell outgrowth from the explants (Stoll et al.,
1997). In actual healing skin wounds, HB-EGF transcript
appears by far the most strongly upregulated (Stoll et al.,
1997). The application of a specific inhibitor of the EGFR
ligand shedding to wound sites in normal mice greatly retards
re-epithelization as the result of a failure in keratinocyte
migration, an effect that can be overcome by the application
of recombinant soluble HB-EGF (Tokumaru et al., 2000). In
EGFR-null mice, re-epithelialization during the first 3 days is
greatly impaired, although this partial block seems to be
overcome by the intervention of other growth factor systems
later on (Repertinger et al., 2004). Remarkably, the wounds of
these mice display an abnormally intense and diffuse
inflammatory cell infiltrate especially rich in neutrophils,
possibly due to an altered chemokine expression in
epidermal keratinocytes. Persistence of an excess pro-
inflammatory infiltrate at the wound site delays wound
closure by the establishment of a hostile, unbalanced
microenvironment, dominated by proteolytic rather than
protective mechanisms (Eming et al., 2007). A human
wound-healing study also demonstrated that topical applica-
tion of recombinant EGF enhanced the healing of split-
thickness wounds (Brown et al., 1989). In cancer patients,
systemic administration of the EGFR inhibitor gefitinib
decreases epithelial proliferation and stratification in res-
ponse to corneal injury (Nakamura et al., 2001). However,
this drug does not impair wound healing following full-
thickness incision (Govindan et al., 2003), suggesting that
redundant growth factor systems are set up in the skin to
successfully replace missing EGFR functions.
EGFR-SPECIFIC EFFECTS ON THE INFLAMMATORY AND
IMMUNE FUNCTIONS OF EPITHELIAL CELLS
Damage to epidermal integrity triggers a cascade of events
that leads to rapid repair of the wound in association with a
robust but transient inflammatory response, in which first
neutrophils and then macrophages and mast cells emigrate
from the nearby tissues or the circulation (Martin and
Leibovich, 2005). The experimental clues suggesting that
the EGFR-ligand system plays a relevant role in the defensive
response mounted by the epithelial cells during wound
healing or in chronic inflammatory skin disorders are quite
recent, and in the following paragraphs the possible
implications of the EGFR system in skin innate immunity
and chronic inflammation are discussed.
Interplay between the mediators of the innate immunity and
EGFR signaling
Epidermal cells can mount effective defenses against micro-
organisms invading the skin. Skin keratinocytes express a
variety of Toll-like receptors (TLRs) (Baker et al., 2003;
Mempel et al., 2003; Pivarcsi et al., 2003), the most
investigated germline-encoded pattern recognition receptors
and probably the primary sensors of innate immunity
(McInturff et al., 2005). Cultured keratinocytes constitutively
express TLR1-6, 9, and 10 mRNA, although only specific
ligands for TLR3–5 and 9 appear functional and result in
differential immune-associated responses (Lebre et al., 2007).
Notably, TGF-a can induce the expression of TLR5 and TLR9
and synergize with these receptors to upregulate the
neutrophil-selective chemoattractant CXC ligand (CXCL)8/
IL-8 and antimicrobial peptides (Miller et al., 2005) (Table 1).
Activation of the TLRs leads to enhanced expression of genes
encoding for an array of antimicrobial peptides, including
defensins and cathelicidins (Selsted and Ouellette, 2005).
These small cationic peptides exert a broad range of actions
against microorganisms, including Gram-positive and
-negative bacteria, fungi, and viruses. A number of anti-
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microbial peptides, which include human b-defensin 3, the
neutrophil gelatinase-associated lipocalin, and secretory
leukocyte protease inhibitor, can be induced by TGF-a in
epidermal keratinocytes (Sørensen et al., 2003) (Table 1).
Even more relevant, upregulated expression of these peptides
following skin wounding critically depends on EGFR signal-
ing rather than the presence of microbial components
(Sørensen et al., 2006). A further level of complexity in the
crosstalk between innate immunity and EGFR-driven events
derives from the finding that the cathelicidin LL-37,
abundantly released also by infiltrating neutrophils, can itself
induce EGFR transactivation through a metalloproteinase-
dependent release of EGFR ligands, leading to improved cell
migration (Tokumaru et al., 2005). Hence, a specific
mediator of the innate immunity sustains intervention of
EGFR-driven regenerative processes and eventually acceler-
ates homeostatic recovery (Raz, 2007). Recently, Niyonsaba
et al. (2007) confirmed that antimicrobial peptides do
stimulate keratinocyte migration and proliferation via an
EGFR-dependent mechanism. In addition, they found that
antimicrobial peptides induce de novo expression of cyto-
kines and T-cell chemoattractants (Niyonsaba et al., 2007),
hence promoting the development of an adaptive immune
response in the skin (Oppenheim and Yang, 2005; Schauber
and Gallo, 2007).
The contribution of keratinocytes to the pathogenesis of
inflammatory skin disorders
A common feature of chronic inflammatory skin disorders,
such as psoriasis, atopic dermatitis, and allergic contact
dermatitis, is epidermal hyperplasia and thickening, a
phenomenon attributed to leukocyte-derived cytokines such
as TNF-a and IFN-g, which are potent inducers of EGF family
growth factors and EGFR (Valyi-Nagy et al., 1992, Matsuura
et al., 1999). These cytokines also initiate a program of
increased expression of inflammatory mediators, which
include adhesion molecules, cytokines, and chemokines
(Pastore et al., 2005a) (Figure 2). Among the chemokines,
the selective neutrophil chemoattractant IL-8 is also active as
a mitogen for epithelial and endothelial cell proliferation
(Tuschil et al., 1992; Addison et al., 2000; Gillitzer and
Goebeler, 2001). In psoriasis, enhanced epidermal IL-8
expression is considered a secondary amplification mecha-
nism leading to epidermal hyperplasia (Reich et al., 2001).
Indeed, IL-8 gene expression is actively induced by the EGFR
ligands abundantly expressed and released in the psoriatic
lesions, including TGF-a (Pastore et al., 2005b) and
amphiregulin (Chokki et al., 2006). In turn, IL-8 could
contribute to activate the metalloprotease-dependent release
of EGFR ligands by acting on its specific GPCR, as already
demonstrated in other epithelial cell systems (Tanida et al.,
2004). Under the effect of pro-inflammatory cytokines,
keratinocytes also release a number of type 1 T-cell chemo-
attractants, including the CXCR3 ligands CXCL10/IP-10,
Table 1. Evidence of EGFR-driven activities on the
immune/inflammatory functions of human epidermal
keratinocytes
Molecules Activity References
Toll-like receptors Upregulation Miller et al. (2005)
TLR5, TLR9







Chemokine Upregulation Mascia et al.
(2003)
CXCL8/IL-8 Miller et al. (2005)
Pastore et al.
(2005b)
Chemokines Downregulation Mascia et al.
(2003)




CXCL, CXC ligand; MCP-1, monocyte chemotactic protein-1; RANTES,
regulated upon activation, normal T-cell expressed.
Leukocyte-derived cytokines:
TNF-α, IFN-γ, IL-17, IL-22...

























Figure 2. Keratinocytes amplify proinflammatory circuits in the skin.
Leukocyte-released cytokines activate a program of enhanced (autocrine
growth factors) or de novo expression of a plethora of chemokines and
cytokines implicated in the recruitment and local activation of immune cells,
including neutrophils (PMN), macrophages (Mf), dendritic cell precursors
(DC), and T cells. The cytokines released by these cell populations, mainly
represented by IL-1, TNF-a, IFN-g, IL-17, and IL-22, are potent activators of
keratinocyte pro-inflammatory functions, including the expression of
membrane molecules (including ICAM-1 and MHC class II molecules)
involved in the retention and further activation of T cells in the epidermis.
EGFR ligands not only are involved in the protective response leading to
epidermal proliferation, but may also perturb the proinflammatory response of
resident and, possibly, infiltrating cell populations through complex
molecular pathways only partially identified. EGFR blockade precipitates a
condition of skin inflammation, whereas active EGFR signaling may favor an
anti-inflammatory condition. However, upregulated expression of
amphiregulin clearly correlates with enhanced skin inflammation. TSLP,
thymic stromal lymphopoietin.
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CXCL9/Mig, and CXCL11/I-TAC, whose expression in kera-
tinocytes is boosted by IFN-g. Keratinocytes also express
potent chemokines with a broad-spectrum activity, which
mainly include CCL2/monocyte chemotactic protein-1 and
CCL5/RANTES (regulated upon activation, normal T-cell
expressed). Epidermal monocyte chemotactic protein-1 is
involved in the early response to injury or irritants, and can
be found in different T-cell-mediated skin disorders, where it
critically contributes to the recruitment of monocyte–macro-
phages, dendritic cells, and T cells. Active immigration of
T cells, monocytes, and neutrophils is also supported by the
increased expression of RANTES by epidermal keratinocytes
(Pastore et al., 2006).
The impact of EGFR-dependent mechanisms on skin
inflammation
The need for an improved understanding of the impact of
EGFR signaling on skin inflammation has become urgent
since the introduction of the previously unknown anti-EGFR
therapies as treatment options for epithelial cancers
(Slichenmyer and Fry, 2001). Currently, a humanized anti-
EGFR mAb (cetuximab) and two small-molecule EGFR
tyrosine kinase inhibitors (gefitinib and erlotinib) have been
approved for patients with colorectal and non-small-cell lung
cancer refractory or intolerant to chemotherapy. In these
patients, a common adverse effect is a papular pustular or
acneiform eruption, which can be severe enough to lead to
treatment modification or cessation (Pe´rez-Soler et al., 2005;
Agero et al., 2006; Hu et al., 2007). These skin lesions are
frequently pruritic and affect mostly the face and the upper
trunk. More important, data from a large number of clinical
trials suggest that there is a direct relationship between
rash incidence and response/survival rate, indicating rash as a
possible marker of effective target inhibition and activity of
EGFR-targeted agents (Pe´rez-Soler and Saltz, 2005). Although
data on the mechanisms are limited, these lesions can
reasonably derive from the impairment of the multiple EGFR-
dependent homeostatic functions of the skin (Lacouture,
2006). Histopathologically, a moderate to severe inflamma-
tory reaction dominated by neutrophils, which surround and
then invade follicular infundibula, characterizes the eruption.
In the epidermis, EGFR is strongly expressed in the basal layer
of epidermal keratinocytes and in the outer root sheath of hair
follicles. Accordingly, mice with an EGFR-dominant negative
mutation have curled wiskers and short hair that become
progressively sparse. Their hair follicles eventually disappear,
accompanied by a macrophage- and multinucleated giant
cell-driven inflammatory reaction (Murillas et al., 1995;
Hansen et al., 1997). Indeed, focal keratinocyte necrosis due
to persistent EGFR inhibition can per se activate and sustain
immune cell recruitment and activation (Li et al., 2001), and
the consequent folliculitis. In human biopsy specimens taken
from affected areas, the stratum corneum is thinner and more
compact. Dry skin with diffuse fine scaling can be frequently
observed after the onset of the papular pustular rash (Agero
et al., 2006) and, despite the sterile nature of the pustules,
secondary bacterial infection with Staphylococcus aureus
may supervene. Hence, an immature skin barrier, combined
with a reduced contribution of EGFR-driven innate immune
mechanisms of the epidermis, could contribute to this
adverse skin reaction.
Animal models predicted a follicle-centered effect of
EGFR inhibitor use. However, they can reasonably provide
only a partial clue about the etiology of the inflammatory rash
in humans treated with anti-EGFR drugs. Interestingly
enough, these drugs can exacerbate skin lesions in psoriatic
patients (Zorzou et al., 2004), and in general they induce a
rash that responds to anti-inflammatory drugs (Lacouture,
2006). We have recently demonstrated that EGFR activation
is involved in the control of chemokine expression in human
keratinocytes. In particular, EGFR activation not only by TGF-
a (Mascia et al., 2003) but also by HB-EGF and amphiregulin
(S Pastore and F Mascia, unpublished observation) potently
downregulates the levels of TNF-a- or IFN-g-induced
RANTES and monocyte chemotactic protein-1, thus poten-
tially opposing the attraction of neutrophils, monocytes/
macrophages, and dendritic cell precursors into lesional skin
(Table 1). Also the immigration of T cells could be impaired
due to EGFR-driven suppression of the CXCR3 ligand IP-10.In
contrast, cultured keratinocytes display a massive upregula-
tion in the levels of these chemokines when EGFR is
effectively blocked (Pastore et al., 2005b). The mechanism
underlying upregulation of these chemokines is a dramatic
stabilization of their transcripts, which is also detectable
when ERK is selectively blocked (Pastore et al., 2005b).
Accordingly, in the mouse models of irritant contact
dermatitis and allergic contact dermatitis, EGFR or ERK
inhibition leads to aggravation of the skin inflammatory
response, with upregulated chemokine expression and
massive skin infiltration by T cells and macrophages
(Figure 3). These data strongly suggest that pharmacological
abrogation of EGFR/ERK signaling pathway worsens skin
inflammation by increasing chemokine expression in kerati-
nocytes. Direct or EGFR-dependent ERK inhibition could also
contribute to skin inflammation by improving the function of
the professional antigen-presenting cells of the skin, as
suggested by the observation that mouse Langerhans cells
enhance their expression of cell membrane costimulatory
molecules, IL-1b, and distinct T-cell chemokines (CCL3/
MIP1a and CCL17/TARC) following selective ERK inhibition
(Fujita et al., 2007). Finally, enhanced expression of a cluster
of pro-inflammatory molecules, including the T-cell-selective
chemoattractants Mig, CX3CL1/fractalkine, and CXCL18/
MIP4, was observed in cervical carcinoma epithelial cells
treated with small-molecule EGFR inhibitors (Woodworth
et al., 2005). Taken together, these independent observations
strongly suggest that targeting EGFR should not be considered
an attractive therapy in the inflammatory disorders associated
with epithelial hyperproliferation, although its efficacy in
the blockade of cell proliferation suggested otherwise
(Ben-Bassat and Klein, 2000).
A relevant body of experimental evidence proofs that the
upregulation of EGFR and itsEGFR ligands are characteristic
features of chronic inflammatory skin disorders such as
psoriasis, and suggests a pathogenic, rather than protective,
role of the EGFR system in skin inflammation. This evidence
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is particularly strong for amphiregulin, whose basal or
suprabasal expression in the skin of transgenic mice leads
to severe psoriasis-like hyperplasia, skin inflammation with a
rich dermal and epidermal infiltration of neutrophils and
lymphocytes, while in the case of suprabasal amphiregulin
expression arthropathy is observed (Cook et al., 1997, 2004).
No clues about the underlying molecular mechanisms are so
far available to explain such a strong neutrophil-rich
inflammatory phenotype, although it seems to be strictly
associated to amphiregulin-specific bioactivity. Indeed,
epidermis targeted expression of TGF-a does not produce
cutaneous inflammatory phenotypes (Vassar and Fuchs,
1991; Dominey et al., 1993). By contrast, the deficiency of
epiregulin results in chronic, epidermal cell-dependent
dermatitis, which correlates with enhanced expression of
the pro-inflammatory cytokine IL-18 by keratinocytes (Shira-
sawa et al., 2004). On the whole, these observations suggest
that the impact of EGFR-dependent mechanisms on inflam-
matory skin responses is a complex, still open issue in which
each single EGFR ligand reasonably contributes with distinct,
if not disparate, effects on resident and/or immigrated cells.
CONCLUDING REMARKS
Beyond its fundamental role for skin development, the EGFR
system is now centrally implicated in all the aspects of skin
homeostasis in the adult life, participating to its continuous
regeneration in health and to the success of wound healing.
Experimental evidence now indicates that its influence
extends to inflammatory and immune functions of the
epidermis, whereas clinical evidence suggests that the
potentiation of the inflammatory response due to EGFR
blockade could relevantly contribute to epithelial cancer
therapy by boosting innate and adaptive antitumor immune
response. Finally, these previously unknown acquisitions
emphasize the importance of this system in skin pathophy-
siology and at the same time underline the limited knowledge
currently available on its complexity.
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